- GENEART wins "European Biotechnica Award", awarded by the Deutsche
Messe AG and its partners
- The award is honouring high innovative strength and a powerful
business concept
- The prestigious prize comprises of cash and non-cash benefits
totalling EUR 100,000
- The British company Astex Therapeutics Limited and the German
company immatics biotechnologies GmbH were honoured as finalists
Regensburg, October 07, 2008 - GENEART AG, the global leader in gene
synthesis and specialist in the field of Synthetic Biology was
awarded the "European Biotechnica Award" during the ceremonial
opening of "Biotechnica 2008" last night. The prize was presented by
the Vice President of the European Commission, Günter Verheugen. The
award comprises of a total of EUR 100,000 and honours innovative
European companies with powerful business concepts in the areas of
biotechnology and life sciences. The winner receives EUR 20,000 in
cash and considerable non-cash benefits. In addition to GENEART, the
companies Astex Therapeutics Limited and immatics biotechnologies
GmbH also reached the final. The prize was awarded for the sixth time
by the Deutsche Messe and its partners. Since its market entrance in
2000, GENEART has revolutionized the gene synthesis and lifted the
production of gene sequences from a manual lab process to a highly
industrialized level. Thereby GENEART provided researchers from
industry and science a cost effective and fast access to gene
sequences. By now, for instance, pharmaceutical companies profit from
this in their development of drugs and vaccines. GENEART is one of
the few biotech companies in Germany, which sustainably does not only
generate sales but also profits. "We are pleased that our work is
validated by the prestigious "European Biotechnica Award". This award
emphasizes GENEART's successful advancement since its foundation, and
the value of our technology for development in red, white and green
biotechnology", stated Prof. Dr. Ralf Wagner, CEO of GENEART AG.
For additional information on the Biotechnica Award, please go to
www.biotechnica.de/award_d
For further inquiries, please contact:
Bernd Merkl
GENEART AG
Josef-Engert-Str. 11
93053 Regensburg
Germany
Phone: +49-(0)941-942 76-638
Fax: +49-(0)941-942 76-711
ir@geneart.com
www.geneart.com
Frank Ostermair
Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Germany
Phone: +49-(0)89-8896906-10
Fax: +49-(0)89-8896906-66
info@better-orange.de
www.better-orange.de
Legal Information
This document may contain estimates, prognoses and opinions about
company plans and objectives, products or services, future results,
opinions about these results or opinions leading up to these results.
All these projections into the future are subject to risk,
uncertainty and unforeseeable change outside the control of the
GENEART Group. Many factors may lead to actual results, which
considerably deviate from the given projections for these results.
About GENEART AG:
In 2000, GENEART entered the gene synthesis market and has since
become the global market leader. Today, the company is one of the
leading specialists in the Synthetic Biology field. Experts at
GENEART provide key technologies for the development and production
of new therapeutics and vaccines. Customers also take advantage of
GENEART services to customize enzyme attributes, such as the
attributes of enzymes used as detergent additives, and to construct
bacteria, which produce complex biopolymers or break down polymers,
such as synthetics, petroleum components, etc. Our production and
service spectrum spans a wide range, from the production of synthetic
genes according to DIN EN ISO 9001-2000, to the creation of gene
libraries in the combinatorial biology, to the development and
production of DNA-based biologically active substances. The GENEART
AG in Regensburg (Germany) and the subsidiaries GENEART Inc. in
Toronto (Canada) and GENEART Inc. in San Francisco (USA) employ more
than 190 people. Since May 2006, GENEART is listed on the German
Stock Exchange.
